Pagibaximab is a chimeric monoclonal antibody for the prevention of staphylococcal sepsis in infants with low birth weight. As of March 2010, it is undergoing Phase II/III clinical trials.

PropertyValue
dbpedia-owl:abstract
  • Pagibaximab is a chimeric monoclonal antibody for the prevention of staphylococcal sepsis in infants with low birth weight. As of March 2010, it is undergoing Phase II/III clinical trials.
dbpedia-owl:atcPrefix
  • none
dbpedia-owl:casNumber
  • 595566-61-3
dbpprop:atcPrefix
  • none
dbpprop:c
  • 6462 (xsd:integer)
dbpprop:casNumber
  • 595566 (xsd:integer)
dbpprop:h
  • 9996 (xsd:integer)
dbpprop:mabType
  • mab
dbpprop:n
  • 1728 (xsd:integer)
dbpprop:o
  • 2028 (xsd:integer)
dbpprop:s
  • 54 (xsd:integer)
dbpprop:source
  • xi/o
dbpprop:target
dbpprop:type
  • mab
dbpprop:verifiedrevid
  • 416115973 (xsd:integer)
dbpprop:wikiPageUsesTemplate
rdf:type
rdfs:comment
  • Pagibaximab is a chimeric monoclonal antibody for the prevention of staphylococcal sepsis in infants with low birth weight. As of March 2010, it is undergoing Phase II/III clinical trials.
rdfs:label
  • Pagibaximab
owl:sameAs
foaf:page
is owl:sameAs of
is foaf:primaryTopic of